Molecular diagnostics tailoring personalized cancer therapy-an oncologist's view.
Cancer
Molecular oncology
Personalized treatment
Precision oncology
Targeted therapy
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
08
07
2023
accepted:
04
11
2023
revised:
27
10
2023
pubmed:
20
11
2023
medline:
20
11
2023
entrez:
20
11
2023
Statut:
ppublish
Résumé
Medical oncology is rapidly evolving with the implementation of personalized, targeted therapies. Advances in molecular diagnostics and the biologic understanding of cancer pathophysiology led to the identification of specific genetic alterations as drivers of cancer progression. Further, improvements in drug development enable the direct interference with these pathways, which allow tailoring personalized treatments based on a distinct molecular characterization of tumors. Thereby, we are currently experiencing a paradigm-shift in the treatment of cancers towards cancer-type agnostic, molecularly targeted, personalized therapies. However, this concept has several important hurdles and limitations to overcome to ultimately increase the proportion of patients benefitting from the precision oncology approach. These include the assessment of clinical relevancy of identified alterations, capturing and interpreting levels of heterogeneity based on intra-tumoral or time-dependent molecular evolution, and challenges in the practical implementation of precision oncology in routine clinical care. In the present review, we summarize the current state of cancer-agnostic precision oncology, discuss the concept of molecular tumor boards, and consider current limitations of personalized cancer therapy. Further, we provide an outlook towards potential future developments including the implementation of functionality assessments of identified genetic alterations and the broader use of liquid biopsies in order to obtain more comprehensive and longitudinal genetic information that might guide personalized cancer therapy in the future.
Identifiants
pubmed: 37982847
doi: 10.1007/s00428-023-03702-7
pii: 10.1007/s00428-023-03702-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-179Informations de copyright
© 2023. The Author(s).
Références
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020) Molecular profiling for precision cancer therapies. Genome Med 12(1):8. https://doi.org/10.1186/s13073-019-0703-1
doi: 10.1186/s13073-019-0703-1
pubmed: 31937368
pmcid: 6961404
Wahida A, Buschhorn L, Fröhling S et al (2022) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3
doi: 10.1038/s41568-022-00529-3
pubmed: 36434139
Brown NA, Elenitoba-Johnson KSJ (2020) Enabling precision oncology through precision diagnostics. Annu Rev Pathol 15:97–121. https://doi.org/10.1146/annurev-pathmechdis-012418-012735
doi: 10.1146/annurev-pathmechdis-012418-012735
pubmed: 31977297
Mateo J, Steuten L, Aftimos P et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28(4):658–665. https://doi.org/10.1038/s41591-022-01717-2
doi: 10.1038/s41591-022-01717-2
pubmed: 35440717
Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17(3):183–196. https://doi.org/10.1038/nrd.2017.226
doi: 10.1038/nrd.2017.226
pubmed: 29217837
Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795. https://doi.org/10.1056/NEJMp1500523
doi: 10.1056/NEJMp1500523
pubmed: 25635347
pmcid: 5101938
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R (2020) Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 86:102019. https://doi.org/10.1016/j.ctrv.2020.102019
doi: 10.1016/j.ctrv.2020.102019
pubmed: 32251926
pmcid: 7272286
van der Velden DL, van Herpen CML, van Laarhoven HWM et al (2017) Molecular tumor boards: current practice and future needs. Ann Oncol 28(12):3070–3075. https://doi.org/10.1093/annonc/mdx528
doi: 10.1093/annonc/mdx528
pubmed: 29045504
Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037. https://doi.org/10.1056/nejm200104053441401
doi: 10.1056/nejm200104053441401
pubmed: 11287972
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/nejm200103153441101
doi: 10.1056/nejm200103153441101
pubmed: 11248153
Berger MF, Mardis ER (2018) The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 15(6):353–365. https://doi.org/10.1038/s41571-018-0002-6
doi: 10.1038/s41571-018-0002-6
pubmed: 29599476
pmcid: 6658089
Weinstein JN, Collisson EA, Mills GB et al (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120. https://doi.org/10.1038/ng.2764
doi: 10.1038/ng.2764
pubmed: 24071849
pmcid: 3919969
Waarts MR, Stonestrom AJ, Park YC, Levine RL (2022) Targeting mutations in cancer. J Clin Invest 132:8. https://doi.org/10.1172/jci154943
doi: 10.1172/jci154943
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275 . Erratum in: Ann Oncol. 2019 May; 30(5):863–870
Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, Mulcahy M, Norden AD, Goldberg SL (2019) Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer. JCO Precis Oncol 3:PO.19.00274. https://doi.org/10.1200/po.19.00274
Lamarca A, Edeline J, Goyal L (2022) How I treat biliary tract cancer. ESMO Open 7(1):100378. https://doi.org/10.1016/j.esmoop.2021.100378
doi: 10.1016/j.esmoop.2021.100378
pubmed: 35032765
pmcid: 8762076
Looney A-M, Nawaz K, Webster RM (2020) Tumour-agnostic therapies. Nat Rev Drug Discov 19(6):383–385
doi: 10.1038/d41573-020-00015-1
pubmed: 32494047
Horak P, Leichsenring J, Goldschmid H et al (2022) Assigning evidence to actionability: an introduction to variant interpretation in precision cancer medicine. Genes Chromosom Cancer 61(6):303–313. https://doi.org/10.1002/gcc.22987
doi: 10.1002/gcc.22987
pubmed: 34331337
Li MM, Datto M, Duncavage EJ et al (2017) Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19(1):4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002
doi: 10.1016/j.jmoldx.2016.10.002
pubmed: 27993330
pmcid: 5707196
Haslam A, Kim MS, Prasad V (2021) Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006–2020. Ann Oncol 32(7):926–932. https://doi.org/10.1016/j.annonc.2021.04.003
doi: 10.1016/j.annonc.2021.04.003
pubmed: 33862157
Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491–1505. https://doi.org/10.1016/j.annonc.2020.07.014
doi: 10.1016/j.annonc.2020.07.014
pubmed: 32853681
Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M (2020) When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 25:100487. https://doi.org/10.1016/j.eclinm.2020.100487
Subbiah V, Kurzrock R (2023) Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J Clin Oncol 41(17):3100–3103. https://doi.org/10.1200/jco.22.02833
doi: 10.1200/jco.22.02833
pubmed: 36930859
Sorscher S. Do all patients diagnosed with cancer deserve germline testing? J Clin Oncol 41(24):4057–4058. https://doi.org/10.1200/jco.23.00710
Colomer R, Miranda J, Romero-Laorden N, Hornedo J, González-Cortijo L, Mouron S, Bueno MJ, Mondéjar R, Quintela-Fandino M (2023) Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement. eClinicalMedicine 60:102029. https://doi.org/10.1016/j.eclinm.2023.102029
Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586–595. https://doi.org/10.1158/2159-8290.Cd-16-1396
doi: 10.1158/2159-8290.Cd-16-1396
pubmed: 28365644
Sicklick JK, Kato S, Okamura R et al (2019) Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25(5):744–750. https://doi.org/10.1038/s41591-019-0407-5
doi: 10.1038/s41591-019-0407-5
pubmed: 31011206
pmcid: 6553618
Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25(5):738–743. https://doi.org/10.1038/s41591-019-0380-z
doi: 10.1038/s41591-019-0380-z
pubmed: 31011204
Von Hoff DD, Stephenson JJ, Rosen P et al (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28(33):4877–4883. https://doi.org/10.1200/jco.2009.26.5983
doi: 10.1200/jco.2009.26.5983
Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795. https://doi.org/10.1158/2159-8290.Cd-21-0126
doi: 10.1158/2159-8290.Cd-21-0126
pubmed: 34112699
Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N (2019) Defining, identifying, and understanding “exceptional responders” in oncology using the tools of precision medicine. Cancer J 25:4
doi: 10.1097/PPO.0000000000000392
Wahida A, Buschhorn L, Fröhling S et al (2023) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3
doi: 10.1038/s41568-022-00529-3
pubmed: 36434139
Rosenquist R, Cuppen E, Buettner R et al (2022) Clinical utility of whole-genome sequencing in precision oncology. Semin Cancer Biol 84:32–39. https://doi.org/10.1016/j.semcancer.2021.06.018
doi: 10.1016/j.semcancer.2021.06.018
pubmed: 34175442
Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-16-1396
doi: 10.1158/2159-8290.cd-16-1396
pubmed: 28365644
Adalsteinsson VA, Ha G, Freeman SS et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1324. https://doi.org/10.1038/s41467-017-00965-y
doi: 10.1038/s41467-017-00965-y
pubmed: 29109393
pmcid: 5673918
Riedl JM, Hasenleithner SO, Pregartner G et al (2021) Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Ther Adv Med Oncol 13:1758835920987658. https://doi.org/10.1177/1758835920987658
doi: 10.1177/1758835920987658
pubmed: 33717225
pmcid: 7923987
Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25(5):738–743. https://doi.org/10.1038/s41591-019-0380-z
doi: 10.1038/s41591-019-0380-z
pubmed: 31011204
Bayle A, Belcaid L, Aldea M et al (2023) Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann Oncol 34(4):389–396. https://doi.org/10.1016/j.annonc.2023.01.008
doi: 10.1016/j.annonc.2023.01.008
pubmed: 36709039
Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71–88. https://doi.org/10.1038/s41576-018-0071-5
doi: 10.1038/s41576-018-0071-5
pubmed: 30410101
Parikh AR, Leshchiner I, Elagina L et al (2019) Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25(9):1415–1421. https://doi.org/10.1038/s41591-019-0561-9
doi: 10.1038/s41591-019-0561-9
pubmed: 31501609
pmcid: 6741444
Kim H, Park KU (2023) Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat 55(2):351–366. https://doi.org/10.4143/crt.2022.1026
doi: 10.4143/crt.2022.1026
pubmed: 36915242
pmcid: 10101787
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. https://doi.org/10.1056/NEJMoa1103782
doi: 10.1056/NEJMoa1103782
pubmed: 21639808
pmcid: 3549296
Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 363(18):1693–1703. https://doi.org/10.1056/NEJMoa1006448
doi: 10.1056/NEJMoa1006448
pubmed: 20979469
pmcid: 3014291
André T, Shiu K-K, Kim TW et al (2020) Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med 383(23):2207–2218. https://doi.org/10.1056/NEJMoa2017699
doi: 10.1056/NEJMoa2017699
pubmed: 33264544
Hellmann MD, Ciuleanu T-E, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104. https://doi.org/10.1056/NEJMoa1801946
doi: 10.1056/NEJMoa1801946
pubmed: 29658845
pmcid: 7193684
Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15(12):731–747. https://doi.org/10.1038/s41571-018-0113-0
doi: 10.1038/s41571-018-0113-0
pubmed: 30333516
pmcid: 6419506
Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated <em>BRAF</em><sup>V600E</sup>-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17(7):984–993. https://doi.org/10.1016/S1470-2045(16)30146-2
doi: 10.1016/S1470-2045(16)30146-2
pubmed: 27283860
pmcid: 4993103
Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med 381(17):1632–1643
doi: 10.1056/NEJMoa1908075
pubmed: 31566309
Li X, Warner JL (2020) A review of precision oncology knowledgebases for determining the clinical actionability of genetic variants. Mini Review. Front Cell Dev Biol 8. https://doi.org/10.3389/fcell.2020.00048
Perakis SO, Weber S, Zhou Q et al (2020) Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open 5(5):e000872. https://doi.org/10.1136/esmoopen-2020-000872
doi: 10.1136/esmoopen-2020-000872
pubmed: 32967919
pmcid: 7513637
Mateo J, Chakravarty D, Dienstmann R et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29(9):1895–1902. https://doi.org/10.1093/annonc/mdy263
doi: 10.1093/annonc/mdy263
pubmed: 30137196
pmcid: 6158764
Luchini C, Lawlor RT, Milella M, Scarpa A (2020) Molecular tumor boards in clinical practice. Trends Cancer 6(9):738–744. https://doi.org/10.1016/j.trecan.2020.05.008
doi: 10.1016/j.trecan.2020.05.008
pubmed: 32517959
Subbiah V, Kurzrock R (2018) Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer 4(2):101–109. https://doi.org/10.1016/j.trecan.2017.12.004
doi: 10.1016/j.trecan.2017.12.004
pubmed: 29458960
pmcid: 5822744
Gardner B, Doose M, Sanchez JI, Freedman AN, de Moor JS (2021) Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study. JCO Precis Oncol 5:PO.21.00109. https://doi.org/10.1200/po.21.00109
Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141(5):877–886. https://doi.org/10.1002/ijc.30828
doi: 10.1002/ijc.30828
pubmed: 28597939
Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20(1):16. https://doi.org/10.1186/s12935-019-1091-8
doi: 10.1186/s12935-019-1091-8
pubmed: 31956294
pmcid: 6958913
Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74. https://doi.org/10.1126/science.aaa4971
doi: 10.1126/science.aaa4971
pubmed: 25838375
Bonneville R, Krook MA, Kautto EA et al (2017) Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 1:1–15. https://doi.org/10.1200/po.17.00073
doi: 10.1200/po.17.00073
Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. New England J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596
doi: 10.1056/NEJMoa1500596
Petrelli F, Ghidini M, Ghidini A, Tomasello G (2020) Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol 6(7):1068–1071. https://doi.org/10.1001/jamaoncol.2020.1046
doi: 10.1001/jamaoncol.2020.1046
pubmed: 32407439
Marabelle A, Fakih M, Lopez J et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9
doi: 10.1016/s1470-2045(20)30445-9
pubmed: 32919526
McGrail DJ, Pilié PG, Rashid NU et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661–672. https://doi.org/10.1016/j.annonc.2021.02.006
doi: 10.1016/j.annonc.2021.02.006
pubmed: 33736924
Hechtman JF (2022) NTRK insights: best practices for pathologists. Mod Pathol 35(3):298–305. https://doi.org/10.1038/s41379-021-00913-8
doi: 10.1038/s41379-021-00913-8
pubmed: 34531526
Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 1:38–46. https://doi.org/10.1038/s41379-019-0324-7
doi: 10.1038/s41379-019-0324-7
Rosen EY, Goldman DA, Hechtman JF et al (2020) TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 26(7):1624–1632. https://doi.org/10.1158/1078-0432.Ccr-19-3165
doi: 10.1158/1078-0432.Ccr-19-3165
pubmed: 31871300
McDermott R, van Tilburg CM, Farago AF et al (2020) 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Ann Oncol 31:S1101–S1102. https://doi.org/10.1016/j.annonc.2020.08.1347
doi: 10.1016/j.annonc.2020.08.1347
Demetri GD, De Braud F, Drilon A et al (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28(7):1302–1312. https://doi.org/10.1158/1078-0432.Ccr-21-3597
doi: 10.1158/1078-0432.Ccr-21-3597
pubmed: 35144967
pmcid: 9365368
Marchiò C, Scaltriti M, Ladanyi M et al (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30(9):1417–1427. https://doi.org/10.1093/annonc/mdz204
doi: 10.1093/annonc/mdz204
pubmed: 31268127
Gerstung M, Jolly C, Leshchiner I et al (2020) The evolutionary history of 2,658 cancers. Nature 578(7793):122–128. https://doi.org/10.1038/s41586-019-1907-7
doi: 10.1038/s41586-019-1907-7
pubmed: 32025013
pmcid: 7054212
Adashek JJ, Kato S, Lippman SM, Kurzrock R (2020) The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med 12(1):16. https://doi.org/10.1186/s13073-020-0714-y
doi: 10.1186/s13073-020-0714-y
pubmed: 32066498
pmcid: 7027240
Letai A, Bhola P, Welm AL (2022) Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40(1):26–35. https://doi.org/10.1016/j.ccell.2021.12.004
doi: 10.1016/j.ccell.2021.12.004
pubmed: 34951956
Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol 18(5):297–312. https://doi.org/10.1038/s41571-020-00457-x
doi: 10.1038/s41571-020-00457-x
pubmed: 33473219
Christofyllakis K, Bittenbring JT, Thurner L et al (2022) Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol Clin Oncol 16(1):21. https://doi.org/10.3892/mco.2021.2453
doi: 10.3892/mco.2021.2453
pubmed: 34909199